{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:30:28Z","timestamp":1776868228978,"version":"3.51.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11427-020-1732-2","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:02:53Z","timestamp":1589587373000},"page":"1515-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19"],"prefix":"10.1007","volume":"63","author":[{"given":"Bo","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenze","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"MAA Al-Bari","year":"2015","unstructured":"Al-Bari, M.A.A. (2015). Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70, 1608\u20131621.","journal-title":"J Antimicrob Chemother"},{"key":"1732_CR2","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-19346\/v1","volume-title":"Immunol Pathol","author":"X Bian","year":"2020","unstructured":"Bian, X., Shi, Z., Chen, R., Cai, J., Wang, C., Xie, J., Zhao, L., Fei, X., Zhang, H., Tan, Y., et al. (2020). Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19. Immunol Pathol, https:\/\/doi.org\/10.21203\/rs.3.rs-19346\/v1."},{"key":"1732_CR3","doi-asserted-by":"crossref","unstructured":"Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Ag 20, 105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"1732_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410","volume-title":"N Engl J Med","author":"J Geleris","year":"2020","unstructured":"Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D., Kubin, C., Barr, R.G., et al. (2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2012410."},{"key":"1732_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","volume-title":"N Engl J Med","author":"J Grein","year":"2020","unstructured":"Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M.L., Lescure, F.X., et al. (2020). Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2007016."},{"key":"1732_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui, D.S.C., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382, 1708\u20131720.","journal-title":"N Engl J Med"},{"key":"1732_CR7","doi-asserted-by":"crossref","unstructured":"He, Y., Xu, Y., Zhang, C., Gao, X., Dykema, K.J., Martin, K.R., Ke, J., Hudson, E.A., Khoo, S.K., Resau, J.H., et al. (2011). Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal 4, ra44.","DOI":"10.1126\/scisignal.2001450"},{"key":"1732_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801.","volume-title":"J Med Virol","author":"P Luo","year":"2020","unstructured":"Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., and Li, J. (2020). Tocilizumab treatment in COVID-19: a single center experience. J Med Virol https:\/\/doi.org\/10.1002\/jmv.25801."},{"key":"1732_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.20065920","volume-title":"MedRxiv","author":"J Magagnoli","year":"2020","unstructured":"Magagnoli, J., Narendran, S., Pereira, F., Cummings, T., Hardin, J., Sutton, S.S., and Ambati, J. (2020). Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv, https:\/\/doi.org\/10.1101\/2020.04.16.20065920."},{"key":"1732_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.10.20060699","volume-title":"MedRxiv","author":"M Mahevas","year":"2020","unstructured":"Mahevas, M., Thi Tran, V., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Gallien, S., Lepeule, R., Szwebel, T.A., Lescure, X., et al. (2020). No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. MedRxiv, https:\/\/doi.org\/10.1101\/2020.04.10.20060699."},{"key":"1732_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0041-008X(67)90089-0","volume":"10","author":"EW McChesney","year":"1967","unstructured":"McChesney, E.W., Banks Jr., W.F., and Fabian, R.J. (1967). Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol Appl Pharmacol 10, 501\u2013513.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1732_CR12","volume-title":"Chinese management guideline for COVID-19 (version 5.0)","author":"National Health Commission of China.","year":"2020","unstructured":"National Health Commission of China. (2020). Chinese management guideline for COVID-19 (version 5.0). http:\/\/wwwnhcgovcn\/yzygj\/s7653p\/202002\/d4b895337e19445f8d728fcaf1e3e13a.shtml."},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"D Plantone","year":"2018","unstructured":"Plantone, D., and Koudriavtseva, T. (2018). Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest 38, 653\u2013671.","journal-title":"Clin Drug Invest"},{"key":"1732_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford, K.D., Parke, A.L., Clifford-Rashotte, M., and Kean, W.F. (2015). Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231\u2013269.","journal-title":"Inflammopharmacology"},{"key":"1732_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","volume":"38","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Riz-zardini, G., Antinori, S., and Galli, M. (2020). COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38, 337\u2013342.","journal-title":"Clin Exp Rheumatol"},{"key":"1732_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ejphar.2018.06.017","volume":"833","author":"H Shiratori","year":"2018","unstructured":"Shiratori, H., Feinweber, C., Luckhardt, S., Wallner, N., Geisslinger, G., Weigert, A., and Parnham, M.J. (2018). An in vitro test system for compounds that modulate human inflammatory macrophage polarization. Eur J Pharmacol 833, 328\u2013338.","journal-title":"Eur J Pharmacol"},{"key":"1732_CR17","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1128\/JVI.02501-05","volume":"80","author":"EJ Snijder","year":"2006","unstructured":"Snijder, E.J., van der Meer, Y., Zevenhoven-Dobbe, J., Onderwater, J.J.M., van der Meulen, J., Koerten, H.K., and Mommaas, A.M. (2006). Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. JVI 80, 5927\u20135940.","journal-title":"JVI"},{"key":"1732_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","volume-title":"Clin Infect Dis","author":"X Yao","year":"2020","unstructured":"Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020). In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis https:\/\/doi.org\/10.1093\/cid\/ciaa237."},{"key":"1732_CR19","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wu, Z., Li, J.W., Zhao, H., and Wang, G.Q. (2020). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Ag 29, 105954.","DOI":"10.1016\/j.ijantimicag.2020.105954"}],"updated-by":[{"DOI":"10.1007\/s11427-020-1751-3","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000}}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-020-1732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-020-1732-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-020-1732-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T17:58:48Z","timestamp":1666547928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-020-1732-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s11427-020-1732-2","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s11427-020-1751-3","asserted-by":"object"}]},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<OrderedList><ListItem><ItemNumber>1.<\/ItemNumber><ItemContent><Para>In the abstract, we missed a piece of information. The correct sentence should be \u201cIn this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation <Emphasis Type=\"Bold\">(63.5%) and oxygen therapy (35.6%)<\/Emphasis> in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020.\u201d<\/Para><\/ItemContent><\/ListItem><ListItem><ItemNumber>2.<\/ItemNumber><ItemContent><Para>We mistakenly put an approval number from Tongji Hospital ethics committee in the paper (IRBID: TJ-C20200113). The correct number should be <Emphasis Type=\"Bold\">TJ-IRB20200229<\/Emphasis>.<\/Para><\/ItemContent><\/ListItem><ListItem><ItemNumber>3.<\/ItemNumber><ItemContent><Para>We mistakenly filled some data in Table 1 and the correct Table 1 (the corrected data are in boldface) should be as follows:<\/Para><\/ItemContent><\/ListItem><\/OrderedList>","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) declare that they have no conflict of interest. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}